Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will host a virtual Key Opinion Leader (KOL) event on the interim efficacy data from the OPTIMIZE-1 Phase 2 study evaluating mitazalimab as first-line treatment for pancreatic cancer patients. The webinar will take place on Tuesday, June 27, 2023 at 9:00 AM ET / 3:00 PM CET. To register for the event, please click here.

The event will feature Dr. Zev Wainberg, Professor of Medicine at University of California, Los Angeles (UCLA) and co-director of the UCLA Gastrointestinal (GI) Oncology Program, who will present the unmet medical need and current treatment landscape for patients suffering from metastatic pancreatic cancer, along with the potential for mitazalimab to provide an effective and safe first-line treatment solution.

Additionally, in a discussion moderated by Alligator Chief Medical Officer Dr. Sumeet Ambarkhane, we will provide insights into the latest interim efficacy readout and survival data from the OPTIMIZE-1 Phase 2 study evaluating CD40 agonist mitazalimab in combination with chemotherapy (mFOLFIRINOX) in 1st line metastatic pancreatic cancer.

As a reminder, the latest interim data analysis published on January 2nd showed encouraging outcomes for pancreatic cancer patients treated with mitazalimab combined with chemotherapy, achieving 52% Objective Response Rate (ORR) and Disease Control Rate (DCR) of >90%.

A live question and answer session will follow the formal presentations.